Article info
PDFResearch ethics
Paper
Assessing risk/benefit for trials using preclinical evidence: a proposal
- Correspondence to Dr Jonathan Kimmelman, STREAM (Studies of Translation, Ethics and Medicine), Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada H3A 1X1; jonathan.kimmelman{at}mcgill.ca
Citation
Assessing risk/benefit for trials using preclinical evidence: a proposal
Publication history
- Received May 1, 2015
- Revised August 14, 2015
- Accepted September 20, 2015
- First published October 13, 2015.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Do we really know how many clinical trials are conducted ethically? Why research ethics committee review practices need to be strengthened and initial steps we could take to strengthen them
- Cell therapy for the preterm infant: promise and practicalities
- Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
- How to keep high-risk studies ethical: classifying candidate solutions
- PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
- First-in-human HIV-remission studies: reducing and justifying risk
- Combined meta-analysis of preclinical cell therapy studies shows overlapping effect modifiers for multiple diseases
- Stem cell-based therapies in neonatology: a new hope
- Efficacy of topical cannabinoids in the management of pain: a systematic review and meta-analysis of animal studies
- Regenerative medicine for neurological diseases—will regenerative neurosurgery deliver?